PGXQP: Ann Moyer, M.D., Ph.D.
Ann Moyer, M.D., Ph.D., co-director of Mayo Clinic’s Molecular Technologies Laboratory, discusses Mayo Clinic Labs’ new focused pharmacogenomics panel. The test uses a real-time, PCR-based testing approach to perform geno- and phenotyping on 10 broadly ap
Episode 96 of the Answers from the Lab podcast, hosted by Mayo Clinic Laboratories, titled "PGXQP: Ann Moyer, M.D., Ph.D." was published on September 14, 2021 and runs 13 minutes.
September 14, 2021 ·13m · Answers from the Lab
Summary
Ann Moyer, M.D., Ph.D., co-director of Mayo Clinic’s Molecular Technologies Laboratory, discusses Mayo Clinic Labs’ new focused pharmacogenomics panel. The test uses a real-time, PCR-based testing approach to perform geno- and phenotyping on 10 broadly applicable genes with known drug-gene associations to provide insight on patient response to a wide range of medications used in several medical specialities.
Episode Description
(00:31)
Dr. Moyer, could you provide us a little bit about you and your background?
(01:18)
Would you mind sharing just a brief overview of the focus pharmacogenomics panel?
(03:32)
So coming back to that patient focus, which patients should have this testing? And when do you recommend to be performed?
(05:17)
Can you talk a little bit about what alternative test options are available and how they compare?
(07:58)
Can you comment on how the results from this test are used in patient care?
(11:55)
Any final thoughts you'd leave us with before we wrap up?
Similar Episodes
Apr 5, 2026 ·6m
Apr 2, 2026 ·5m
Mar 29, 2026 ·7m
Mar 19, 2026 ·5m
Mar 15, 2026 ·7m
Mar 9, 2026 ·12m